This is as of $15/share last week. Maybe a few million net have covered since then, though there wasn't any covering when it ran up to 18-19 in May or June. The bulk of the repricing is yet to come imo $LQDA

Is this satire?

What stands out from the quotes is how patients did the research on their own and asked for Yutrepia. This makes everything much easier for $LQDA

5 days to cover and counting (down)

I am rarely confident enough to make predictions about The Future but I am 100% certain that the singularity will not be brought about by a dude whose bio is "AI is cool i guess" and frankly if you don't understand this you need to redo junior high

$LQDA short interest back down (very slightly) to 21m or 35% of the float. That's as of $19/share, with ER tomorrow. Sitting ducks if you ask me

When the PH company sells its PH drug $LQDA

If you really go through this $LQDA report, it represents the sort of step-change difference in circumstances that often takes buy side and sell side folks a while to really comprehend - because it is so shocking from everyone's initial assumptions going into this launch

I sense the $LQDA shorts are finally covering. I originally had mid-2025 fair value pegged between 25-35 and we're there, but the call was nuts. They're even going after Uptravi. You can't model execution at the far right tail. That said, I expect the stock to stabilize soon

$LQDA short interest… Not too crazy 🤷🏼‍♂️ given recent volume